An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Brain metastases; Male breast cancer
- Focus Therapeutic Use
- Acronyms PATRICIA
- Sponsors Genentech
- 12 Apr 2018 Planned End Date changed from 28 Jun 2019 to 29 May 2020.
- 12 Apr 2018 Planned primary completion date changed from 28 Jun 2019 to 29 May 2020.
- 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.